Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POTESTA: Nitrous oxide plus traumatic script exposure for PTSD
2026-525826-39-00Phase 2Authorised
- Sponsor
- CHRU Tours
- Start
- Aug 2026
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitrous oxide + oxygen in post-traumatic stress disorder (PTSD) (2 arms), sponsored by CHRU Tours. Primary endpoint: CAPS-5 change at 3 months. Planned start Aug 2026; status: authorised.
02
Drugs
nitrous oxide + oxygen
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on 2026-525826-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525826-39-00.